Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism

Michael Andrew Murias, Samantha Major, Scott Compton, Jessica Buttinger, Jessica M. Sun, Joanne Kurtzberg, Geraldine Dawson*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study was a phase I, single-center, and open-label trial of a single intravenous infusion of autologous umbilical cord blood in young children with autism spectrum disorder (ASD). Twenty-five children between the ages of 2 and 6 with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were enrolled. Safety results and clinical outcomes measured at 6 and 12 months post-infusion have been previously published. The purpose of the present analysis was to explore whether measures of electroencephalography (EEG) theta, alpha, and beta power showed evidence of change after treatment and whether baseline EEG characteristics were predictive of clinical improvement. The primary endpoint was the parent-reported Vineland adaptive behavior scales-II socialization subscale score, collected at baseline, 6- and 12-month visits. In addition, the expressive one word picture vocabulary test 4 and the clinical global impression-improvement scale were administered. Electrophysiological recordings were taken during viewing of dynamic social and nonsocial stimuli at 6 and 12 months post-treatment. Significant changes in EEG spectral characteristics were found by 12 months post-infusion, which were characterized by increased alpha and beta power and decreased EEG theta power. Furthermore, higher baseline posterior EEG beta power was associated with a greater degree of improvement in social communication symptoms, highlighting the potential for an EEG biomarker to predict variation in outcome. Taken together, the results suggest that EEG measures may be useful endpoints for future ASD clinical trials. Stem Cells Translational Medicine 2018;7:783–791.

Original languageEnglish (US)
Pages (from-to)783-791
Number of pages9
JournalStem Cells Translational Medicine
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Autistic Disorder
Fetal Blood
Electroencephalography
Biomarkers
Therapeutics
Language Tests
Translational Medical Research
Socialization
Psychological Adaptation
Intravenous Infusions
Stem Cells
Communication
Clinical Trials
Safety
Power (Psychology)
Autism Spectrum Disorder

Keywords

  • Autologous
  • Umbilical cord blood

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Murias, Michael Andrew ; Major, Samantha ; Compton, Scott ; Buttinger, Jessica ; Sun, Jessica M. ; Kurtzberg, Joanne ; Dawson, Geraldine. / Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism. In: Stem Cells Translational Medicine. 2018 ; Vol. 7, No. 11. pp. 783-791.
@article{f5957f4907ce4144bccb52ee58061e0a,
title = "Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism",
abstract = "This study was a phase I, single-center, and open-label trial of a single intravenous infusion of autologous umbilical cord blood in young children with autism spectrum disorder (ASD). Twenty-five children between the ages of 2 and 6 with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were enrolled. Safety results and clinical outcomes measured at 6 and 12 months post-infusion have been previously published. The purpose of the present analysis was to explore whether measures of electroencephalography (EEG) theta, alpha, and beta power showed evidence of change after treatment and whether baseline EEG characteristics were predictive of clinical improvement. The primary endpoint was the parent-reported Vineland adaptive behavior scales-II socialization subscale score, collected at baseline, 6- and 12-month visits. In addition, the expressive one word picture vocabulary test 4 and the clinical global impression-improvement scale were administered. Electrophysiological recordings were taken during viewing of dynamic social and nonsocial stimuli at 6 and 12 months post-treatment. Significant changes in EEG spectral characteristics were found by 12 months post-infusion, which were characterized by increased alpha and beta power and decreased EEG theta power. Furthermore, higher baseline posterior EEG beta power was associated with a greater degree of improvement in social communication symptoms, highlighting the potential for an EEG biomarker to predict variation in outcome. Taken together, the results suggest that EEG measures may be useful endpoints for future ASD clinical trials. Stem Cells Translational Medicine 2018;7:783–791.",
keywords = "Autologous, Umbilical cord blood",
author = "Murias, {Michael Andrew} and Samantha Major and Scott Compton and Jessica Buttinger and Sun, {Jessica M.} and Joanne Kurtzberg and Geraldine Dawson",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/sctm.18-0090",
language = "English (US)",
volume = "7",
pages = "783--791",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "11",

}

Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism. / Murias, Michael Andrew; Major, Samantha; Compton, Scott; Buttinger, Jessica; Sun, Jessica M.; Kurtzberg, Joanne; Dawson, Geraldine.

In: Stem Cells Translational Medicine, Vol. 7, No. 11, 01.11.2018, p. 783-791.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism

AU - Murias, Michael Andrew

AU - Major, Samantha

AU - Compton, Scott

AU - Buttinger, Jessica

AU - Sun, Jessica M.

AU - Kurtzberg, Joanne

AU - Dawson, Geraldine

PY - 2018/11/1

Y1 - 2018/11/1

N2 - This study was a phase I, single-center, and open-label trial of a single intravenous infusion of autologous umbilical cord blood in young children with autism spectrum disorder (ASD). Twenty-five children between the ages of 2 and 6 with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were enrolled. Safety results and clinical outcomes measured at 6 and 12 months post-infusion have been previously published. The purpose of the present analysis was to explore whether measures of electroencephalography (EEG) theta, alpha, and beta power showed evidence of change after treatment and whether baseline EEG characteristics were predictive of clinical improvement. The primary endpoint was the parent-reported Vineland adaptive behavior scales-II socialization subscale score, collected at baseline, 6- and 12-month visits. In addition, the expressive one word picture vocabulary test 4 and the clinical global impression-improvement scale were administered. Electrophysiological recordings were taken during viewing of dynamic social and nonsocial stimuli at 6 and 12 months post-treatment. Significant changes in EEG spectral characteristics were found by 12 months post-infusion, which were characterized by increased alpha and beta power and decreased EEG theta power. Furthermore, higher baseline posterior EEG beta power was associated with a greater degree of improvement in social communication symptoms, highlighting the potential for an EEG biomarker to predict variation in outcome. Taken together, the results suggest that EEG measures may be useful endpoints for future ASD clinical trials. Stem Cells Translational Medicine 2018;7:783–791.

AB - This study was a phase I, single-center, and open-label trial of a single intravenous infusion of autologous umbilical cord blood in young children with autism spectrum disorder (ASD). Twenty-five children between the ages of 2 and 6 with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were enrolled. Safety results and clinical outcomes measured at 6 and 12 months post-infusion have been previously published. The purpose of the present analysis was to explore whether measures of electroencephalography (EEG) theta, alpha, and beta power showed evidence of change after treatment and whether baseline EEG characteristics were predictive of clinical improvement. The primary endpoint was the parent-reported Vineland adaptive behavior scales-II socialization subscale score, collected at baseline, 6- and 12-month visits. In addition, the expressive one word picture vocabulary test 4 and the clinical global impression-improvement scale were administered. Electrophysiological recordings were taken during viewing of dynamic social and nonsocial stimuli at 6 and 12 months post-treatment. Significant changes in EEG spectral characteristics were found by 12 months post-infusion, which were characterized by increased alpha and beta power and decreased EEG theta power. Furthermore, higher baseline posterior EEG beta power was associated with a greater degree of improvement in social communication symptoms, highlighting the potential for an EEG biomarker to predict variation in outcome. Taken together, the results suggest that EEG measures may be useful endpoints for future ASD clinical trials. Stem Cells Translational Medicine 2018;7:783–791.

KW - Autologous

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=85053195481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053195481&partnerID=8YFLogxK

U2 - 10.1002/sctm.18-0090

DO - 10.1002/sctm.18-0090

M3 - Article

C2 - 30070044

AN - SCOPUS:85053195481

VL - 7

SP - 783

EP - 791

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 11

ER -